NeoGenomics更新了2024财政年度指南,EPS为0.080-0.100美元,收入为655M-667M美元。 NeoGenomics updates FY 2024 guidance with EPS of $0.080-0.100 and revenue of $655M-$667M.

新基因组学更新了其2024财政年度收入指导,预测EPS在0.080-0.100美元之间,收入在655M-667M美元之间。 NeoGenomics updated its FY 2024 earnings guidance, projecting EPS between $0.080-0.100 and revenue between $655M-$667M. 该公司进行癌症检测,并拥有“机动购买”评级。 The company operates in cancer testing and has a "Moderate Buy" rating. Neogen公司报告,与预期相比,Q2收入较好,每股0.11美元,收入2.3130亿美元,但由于非现金商誉减值收费,其2025财政年度收入预测减至90.5万至92.5亿美元。 Neogen Corp. reported better-than-expected Q2 earnings of $0.11 per share and revenue of $231.30 million, but trimmed its FY 2025 revenue forecast to $905M-$925M due to a non-cash goodwill impairment charge.